Predicted effect of direct acting antivirals in the current HIV―HCV-coinfected population in Spain
Direct acting antivirals (DAAs) against HCV are eagerly awaited for HIV-HCV-coinfected individuals. However, the activity of first generation drugs is limited to HCV genotype 1 and is lower in cirrhotics, subtype 1a infections, prior interferon (IFN)-α exposure or unfavourable IL28B alleles. Herein,...
Gespeichert in:
| Veröffentlicht in: | Antiviral therapy 2012-01, Vol.17 (3), p.571-575 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 575 |
|---|---|
| container_issue | 3 |
| container_start_page | 571 |
| container_title | Antiviral therapy |
| container_volume | 17 |
| creator | POVEDA, Eva VISPO, Eugenia BARREIRO, Pablo DE MENDOZA, Carmen LABARGA, Pablo VICENTE FERNANDEZ-MONTERO, Jose MARTIN-CARBONERO, Luz SORIANO, Vincent |
| description | Direct acting antivirals (DAAs) against HCV are eagerly awaited for HIV-HCV-coinfected individuals. However, the activity of first generation drugs is limited to HCV genotype 1 and is lower in cirrhotics, subtype 1a infections, prior interferon (IFN)-α exposure or unfavourable IL28B alleles. Herein, we report the current profile of HIV-HCV-coinfected patients at our institution in an attempt to predict the effect of DAAs.
All HIV-HCV-coinfected patients seen at our HIV outpatient clinic in 2011 were identified. Information on serum HCV RNA, HCV genotype/subtype, plasma HIV RNA, prior IFN-α experience, liver fibrosis staging and IL28B alleles was recorded.
A total of 424 HIV-HCV-coinfected patients were identified, of whom 174 (41%) were IFN-α-experienced. Mean serum HCV RNA was 6 log IU/ml. HCV genotype/subtype distribution was 166 (39.1%) G1a, 93 (22%) G1b, 85 (20%) G4, 49 (11.5%) G3 and 1 ( |
| doi_str_mv | 10.3851/IMP1992 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1010476395</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1010476395</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-f065f62f8ff1f1d2eef114f7bc3357926c107085ad63ae176bfd08bdea4630f13</originalsourceid><addsrcrecordid>eNpF0LtOwzAYBWALgWgpiDdAXhAsAV9iJxlRBbRSEZWArpHjCxilTrAdJDZeghfkSUjUAtP_D985wwHgGKMLmjN8Ob9b4qIgO2BMUIoSgli-C8aYsiLhjLIROAjhFSGSFwjtgxEhpKAcZWOgll4rK6NWUBujZYSNgcr64RMyWvcMhYv23XpRB2gdjC8ays577SKczVffn1-z6SqRjXVDuq9pm7arRbSNG_hDK6w7BHumj-uj7Z2Ap5vrx-ksWdzfzqdXi0TSNI2JQZwZTkxuDDZYEa0NxqnJKkkpywrCJUYZyplQnAqNM14ZhfJKaZFyigymE3C-6W1989bpEMu1DVLXtXC66UKJEUZpxmnBenq2odI3IXhtytbbtfAfPSqHScvtpL082ZZ21VqrP_e7YQ9Ot0AEKWrjhZM2_DtWkLRn9AeqW365</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1010476395</pqid></control><display><type>article</type><title>Predicted effect of direct acting antivirals in the current HIV―HCV-coinfected population in Spain</title><source>MEDLINE</source><source>Sage Journals GOLD Open Access 2024</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>POVEDA, Eva ; VISPO, Eugenia ; BARREIRO, Pablo ; DE MENDOZA, Carmen ; LABARGA, Pablo ; VICENTE FERNANDEZ-MONTERO, Jose ; MARTIN-CARBONERO, Luz ; SORIANO, Vincent</creator><creatorcontrib>POVEDA, Eva ; VISPO, Eugenia ; BARREIRO, Pablo ; DE MENDOZA, Carmen ; LABARGA, Pablo ; VICENTE FERNANDEZ-MONTERO, Jose ; MARTIN-CARBONERO, Luz ; SORIANO, Vincent</creatorcontrib><description>Direct acting antivirals (DAAs) against HCV are eagerly awaited for HIV-HCV-coinfected individuals. However, the activity of first generation drugs is limited to HCV genotype 1 and is lower in cirrhotics, subtype 1a infections, prior interferon (IFN)-α exposure or unfavourable IL28B alleles. Herein, we report the current profile of HIV-HCV-coinfected patients at our institution in an attempt to predict the effect of DAAs.
All HIV-HCV-coinfected patients seen at our HIV outpatient clinic in 2011 were identified. Information on serum HCV RNA, HCV genotype/subtype, plasma HIV RNA, prior IFN-α experience, liver fibrosis staging and IL28B alleles was recorded.
A total of 424 HIV-HCV-coinfected patients were identified, of whom 174 (41%) were IFN-α-experienced. Mean serum HCV RNA was 6 log IU/ml. HCV genotype/subtype distribution was 166 (39.1%) G1a, 93 (22%) G1b, 85 (20%) G4, 49 (11.5%) G3 and 1 (<1%) G2, and 30 (7%) were unclassified. Of note, 56% of G1a were prior IFN-α-experienced patients. Overall, 37% had advanced liver fibrosis (Metavir score estimates F3-F4). Finally, 70% harboured unfavourable IL28B alleles.
The current profile of HIV-HCV-coinfected patients in Spain is dominated by particularly difficult-to-treat individuals, such as those infected with G1a or G4 (59%), advanced liver fibrosis (37%) and unfavourable IL28B alleles (70%). A wide use of prior anti-HCV therapy in our region most likely has resulted in hepatitis C cure of more IFN-α susceptible individuals, with accumulation of a more refractory treatment population. Thus, the use of DAAs in HIV-HCV-coinfected patients will require particular expertise and their benefit might be lower than expected.</description><identifier>ISSN: 1359-6535</identifier><identifier>EISSN: 2040-2058</identifier><identifier>DOI: 10.3851/IMP1992</identifier><identifier>PMID: 22293607</identifier><language>eng</language><publisher>London: International Medical Press</publisher><subject>Adult ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - pharmacology ; Antiviral Agents - therapeutic use ; Biological and medical sciences ; Coinfection - drug therapy ; Coinfection - virology ; Female ; Genotype ; Hepacivirus - classification ; Hepacivirus - drug effects ; Hepacivirus - genetics ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - virology ; HIV Infections - complications ; HIV Infections - drug therapy ; HIV Infections - virology ; HIV-1 - drug effects ; Human viral diseases ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Infectious diseases ; Interferons ; Interleukins - genetics ; Liver Cirrhosis - drug therapy ; Liver Cirrhosis - pathology ; Liver Cirrhosis - virology ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Predictive Value of Tests ; Spain ; Treatment Outcome ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viral hepatitis</subject><ispartof>Antiviral therapy, 2012-01, Vol.17 (3), p.571-575</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-f065f62f8ff1f1d2eef114f7bc3357926c107085ad63ae176bfd08bdea4630f13</citedby><cites>FETCH-LOGICAL-c344t-f065f62f8ff1f1d2eef114f7bc3357926c107085ad63ae176bfd08bdea4630f13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25924073$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22293607$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>POVEDA, Eva</creatorcontrib><creatorcontrib>VISPO, Eugenia</creatorcontrib><creatorcontrib>BARREIRO, Pablo</creatorcontrib><creatorcontrib>DE MENDOZA, Carmen</creatorcontrib><creatorcontrib>LABARGA, Pablo</creatorcontrib><creatorcontrib>VICENTE FERNANDEZ-MONTERO, Jose</creatorcontrib><creatorcontrib>MARTIN-CARBONERO, Luz</creatorcontrib><creatorcontrib>SORIANO, Vincent</creatorcontrib><title>Predicted effect of direct acting antivirals in the current HIV―HCV-coinfected population in Spain</title><title>Antiviral therapy</title><addtitle>Antivir Ther</addtitle><description>Direct acting antivirals (DAAs) against HCV are eagerly awaited for HIV-HCV-coinfected individuals. However, the activity of first generation drugs is limited to HCV genotype 1 and is lower in cirrhotics, subtype 1a infections, prior interferon (IFN)-α exposure or unfavourable IL28B alleles. Herein, we report the current profile of HIV-HCV-coinfected patients at our institution in an attempt to predict the effect of DAAs.
All HIV-HCV-coinfected patients seen at our HIV outpatient clinic in 2011 were identified. Information on serum HCV RNA, HCV genotype/subtype, plasma HIV RNA, prior IFN-α experience, liver fibrosis staging and IL28B alleles was recorded.
A total of 424 HIV-HCV-coinfected patients were identified, of whom 174 (41%) were IFN-α-experienced. Mean serum HCV RNA was 6 log IU/ml. HCV genotype/subtype distribution was 166 (39.1%) G1a, 93 (22%) G1b, 85 (20%) G4, 49 (11.5%) G3 and 1 (<1%) G2, and 30 (7%) were unclassified. Of note, 56% of G1a were prior IFN-α-experienced patients. Overall, 37% had advanced liver fibrosis (Metavir score estimates F3-F4). Finally, 70% harboured unfavourable IL28B alleles.
The current profile of HIV-HCV-coinfected patients in Spain is dominated by particularly difficult-to-treat individuals, such as those infected with G1a or G4 (59%), advanced liver fibrosis (37%) and unfavourable IL28B alleles (70%). A wide use of prior anti-HCV therapy in our region most likely has resulted in hepatitis C cure of more IFN-α susceptible individuals, with accumulation of a more refractory treatment population. Thus, the use of DAAs in HIV-HCV-coinfected patients will require particular expertise and their benefit might be lower than expected.</description><subject>Adult</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - pharmacology</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Coinfection - drug therapy</subject><subject>Coinfection - virology</subject><subject>Female</subject><subject>Genotype</subject><subject>Hepacivirus - classification</subject><subject>Hepacivirus - drug effects</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - virology</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - virology</subject><subject>HIV-1 - drug effects</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Infectious diseases</subject><subject>Interferons</subject><subject>Interleukins - genetics</subject><subject>Liver Cirrhosis - drug therapy</subject><subject>Liver Cirrhosis - pathology</subject><subject>Liver Cirrhosis - virology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Predictive Value of Tests</subject><subject>Spain</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viral hepatitis</subject><issn>1359-6535</issn><issn>2040-2058</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0LtOwzAYBWALgWgpiDdAXhAsAV9iJxlRBbRSEZWArpHjCxilTrAdJDZeghfkSUjUAtP_D985wwHgGKMLmjN8Ob9b4qIgO2BMUIoSgli-C8aYsiLhjLIROAjhFSGSFwjtgxEhpKAcZWOgll4rK6NWUBujZYSNgcr64RMyWvcMhYv23XpRB2gdjC8ays577SKczVffn1-z6SqRjXVDuq9pm7arRbSNG_hDK6w7BHumj-uj7Z2Ap5vrx-ksWdzfzqdXi0TSNI2JQZwZTkxuDDZYEa0NxqnJKkkpywrCJUYZyplQnAqNM14ZhfJKaZFyigymE3C-6W1989bpEMu1DVLXtXC66UKJEUZpxmnBenq2odI3IXhtytbbtfAfPSqHScvtpL082ZZ21VqrP_e7YQ9Ot0AEKWrjhZM2_DtWkLRn9AeqW365</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>POVEDA, Eva</creator><creator>VISPO, Eugenia</creator><creator>BARREIRO, Pablo</creator><creator>DE MENDOZA, Carmen</creator><creator>LABARGA, Pablo</creator><creator>VICENTE FERNANDEZ-MONTERO, Jose</creator><creator>MARTIN-CARBONERO, Luz</creator><creator>SORIANO, Vincent</creator><general>International Medical Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120101</creationdate><title>Predicted effect of direct acting antivirals in the current HIV―HCV-coinfected population in Spain</title><author>POVEDA, Eva ; VISPO, Eugenia ; BARREIRO, Pablo ; DE MENDOZA, Carmen ; LABARGA, Pablo ; VICENTE FERNANDEZ-MONTERO, Jose ; MARTIN-CARBONERO, Luz ; SORIANO, Vincent</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-f065f62f8ff1f1d2eef114f7bc3357926c107085ad63ae176bfd08bdea4630f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - pharmacology</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Coinfection - drug therapy</topic><topic>Coinfection - virology</topic><topic>Female</topic><topic>Genotype</topic><topic>Hepacivirus - classification</topic><topic>Hepacivirus - drug effects</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - virology</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - virology</topic><topic>HIV-1 - drug effects</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Infectious diseases</topic><topic>Interferons</topic><topic>Interleukins - genetics</topic><topic>Liver Cirrhosis - drug therapy</topic><topic>Liver Cirrhosis - pathology</topic><topic>Liver Cirrhosis - virology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Predictive Value of Tests</topic><topic>Spain</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>POVEDA, Eva</creatorcontrib><creatorcontrib>VISPO, Eugenia</creatorcontrib><creatorcontrib>BARREIRO, Pablo</creatorcontrib><creatorcontrib>DE MENDOZA, Carmen</creatorcontrib><creatorcontrib>LABARGA, Pablo</creatorcontrib><creatorcontrib>VICENTE FERNANDEZ-MONTERO, Jose</creatorcontrib><creatorcontrib>MARTIN-CARBONERO, Luz</creatorcontrib><creatorcontrib>SORIANO, Vincent</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Antiviral therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>POVEDA, Eva</au><au>VISPO, Eugenia</au><au>BARREIRO, Pablo</au><au>DE MENDOZA, Carmen</au><au>LABARGA, Pablo</au><au>VICENTE FERNANDEZ-MONTERO, Jose</au><au>MARTIN-CARBONERO, Luz</au><au>SORIANO, Vincent</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predicted effect of direct acting antivirals in the current HIV―HCV-coinfected population in Spain</atitle><jtitle>Antiviral therapy</jtitle><addtitle>Antivir Ther</addtitle><date>2012-01-01</date><risdate>2012</risdate><volume>17</volume><issue>3</issue><spage>571</spage><epage>575</epage><pages>571-575</pages><issn>1359-6535</issn><eissn>2040-2058</eissn><abstract>Direct acting antivirals (DAAs) against HCV are eagerly awaited for HIV-HCV-coinfected individuals. However, the activity of first generation drugs is limited to HCV genotype 1 and is lower in cirrhotics, subtype 1a infections, prior interferon (IFN)-α exposure or unfavourable IL28B alleles. Herein, we report the current profile of HIV-HCV-coinfected patients at our institution in an attempt to predict the effect of DAAs.
All HIV-HCV-coinfected patients seen at our HIV outpatient clinic in 2011 were identified. Information on serum HCV RNA, HCV genotype/subtype, plasma HIV RNA, prior IFN-α experience, liver fibrosis staging and IL28B alleles was recorded.
A total of 424 HIV-HCV-coinfected patients were identified, of whom 174 (41%) were IFN-α-experienced. Mean serum HCV RNA was 6 log IU/ml. HCV genotype/subtype distribution was 166 (39.1%) G1a, 93 (22%) G1b, 85 (20%) G4, 49 (11.5%) G3 and 1 (<1%) G2, and 30 (7%) were unclassified. Of note, 56% of G1a were prior IFN-α-experienced patients. Overall, 37% had advanced liver fibrosis (Metavir score estimates F3-F4). Finally, 70% harboured unfavourable IL28B alleles.
The current profile of HIV-HCV-coinfected patients in Spain is dominated by particularly difficult-to-treat individuals, such as those infected with G1a or G4 (59%), advanced liver fibrosis (37%) and unfavourable IL28B alleles (70%). A wide use of prior anti-HCV therapy in our region most likely has resulted in hepatitis C cure of more IFN-α susceptible individuals, with accumulation of a more refractory treatment population. Thus, the use of DAAs in HIV-HCV-coinfected patients will require particular expertise and their benefit might be lower than expected.</abstract><cop>London</cop><pub>International Medical Press</pub><pmid>22293607</pmid><doi>10.3851/IMP1992</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-6535 |
| ispartof | Antiviral therapy, 2012-01, Vol.17 (3), p.571-575 |
| issn | 1359-6535 2040-2058 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1010476395 |
| source | MEDLINE; Sage Journals GOLD Open Access 2024; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Biological and medical sciences Coinfection - drug therapy Coinfection - virology Female Genotype Hepacivirus - classification Hepacivirus - drug effects Hepacivirus - genetics Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology HIV Infections - complications HIV Infections - drug therapy HIV Infections - virology HIV-1 - drug effects Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Interferons Interleukins - genetics Liver Cirrhosis - drug therapy Liver Cirrhosis - pathology Liver Cirrhosis - virology Male Medical sciences Middle Aged Pharmacology. Drug treatments Predictive Value of Tests Spain Treatment Outcome Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral hepatitis |
| title | Predicted effect of direct acting antivirals in the current HIV―HCV-coinfected population in Spain |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T18%3A02%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predicted%20effect%20of%20direct%20acting%20antivirals%20in%20the%20current%20HIV%E2%80%95HCV-coinfected%20population%20in%20Spain&rft.jtitle=Antiviral%20therapy&rft.au=POVEDA,%20Eva&rft.date=2012-01-01&rft.volume=17&rft.issue=3&rft.spage=571&rft.epage=575&rft.pages=571-575&rft.issn=1359-6535&rft.eissn=2040-2058&rft_id=info:doi/10.3851/IMP1992&rft_dat=%3Cproquest_cross%3E1010476395%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1010476395&rft_id=info:pmid/22293607&rfr_iscdi=true |